KN-052

N/A

Report date: 2024/06/11 20:00:08

Base Information

Drug NameKN-052

Drug Alias NameKN-052

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionImmunomodulatorsProgrammed death-ligand 1 blockersTumor necrosis factor receptor superfamily member 4 agonists

TargetsProgrammed death-ligand 1Tumor necrosis factor receptor superfamily member 4

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaDiscontinued

Originator CompaniesSuzhou Alphamab Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesN/A

Inactive CompaniesJiangsu Alphamab Biopharmaceuticals Co Ltd

Active IndicationsN/A

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A